Integral Diagnostics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Ian Kadish

Chief executive officer

AU$1.1m

Total compensation

CEO salary percentage	71.2%
CEO tenure	7yrs
CEO ownership	0.2%
Management average tenure	3.7yrs
Board average tenure	1.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ian Kadish's remuneration changed compared to Integral Diagnostics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-AU$58m
Sep 30 2023	n/a	n/a	-AU$16m
Jun 30 2023	AU$1m	AU$782k	AU$25m
Mar 31 2023	n/a	n/a	AU$23m
Dec 31 2022	n/a	n/a	AU$21m
Sep 30 2022	n/a	n/a	AU$18m
Jun 30 2022	n/a	AU$781k	AU$15m
Mar 31 2022	n/a	n/a	AU$18m
Dec 31 2021	n/a	n/a	AU$22m
Sep 30 2021	n/a	n/a	AU$26m
Jun 30 2021	AU$2m	AU$736k	AU$31m
Mar 31 2021	n/a	n/a	AU$32m
Dec 31 2020	n/a	n/a	AU$32m
Sep 30 2020	n/a	n/a	AU$28m
Jun 30 2020	AU$1m	AU$635k	AU$23m
Mar 31 2020	n/a	n/a	AU$22m
Dec 31 2019	n/a	n/a	AU$21m
Sep 30 2019	n/a	n/a	AU$21m
Jun 30 2019	AU$876k	AU$549k	AU$21m
Mar 31 2019	n/a	n/a	AU$19m
Dec 31 2018	n/a	n/a	AU$17m
Sep 30 2018	n/a	n/a	AU$16m
Jun 30 2018	AU$711k	AU$489k	AU$15m
Mar 31 2018	n/a	n/a	AU$15m
Dec 31 2017	n/a	n/a	AU$15m
Sep 30 2017	n/a	n/a	AU$15m
Jun 30 2017	AU$50k	AU$44k	AU$15m

Compensation vs Market: Ian's total compensation ($USD728.71K) is about average for companies of similar size in the Australian market ($USD777.29K).

Compensation vs Earnings: Ian's compensation has increased whilst the company is unprofitable.

CEO

Ian Kadish (60 yo)

7yrs

Tenure

AU$1,097,723

Compensation

Dr. Ian Kadish, MBBCh, MBA, has been the Chief Executive Officer, Managing Director and Director at Integral Diagnostics Limited since May 22, 2017. Dr. Kadish serves as Independent Non-Executive Director...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ian Kadish	CEO, MD & Director	7yrs	AU$1.10m	0.24% A$ 1.4m
Jacqueline Milne	Executive Director	4.5yrs	AU$1.05m	0.011% A$ 61.0k
Scott Paterson	Chief Financial Officer	less than a year	no data	no data
Julian Gully	Chief Information Officer	4.7yrs	no data	no data
Nikki Valle	General Counsel & Company Secretary	less than a year	no data	no data
Lisa Sorger	Chief Medical Officer	2.8yrs	no data	no data

3.7yrs

Average Tenure

Experienced Management: IDX's management team is considered experienced (3.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ian Kadish	CEO, MD & Director	no data	AU$1.10m	0.24% A$ 1.4m
Jacqueline Milne	Executive Director	4.5yrs	AU$1.05m	0.011% A$ 61.0k
Raelene Murphy	Independent Non-Executive Director	6.6yrs	AU$137.50k	0.013% A$ 74.9k
Andrew Fay	Independent Non-Executive Director	1.8yrs	AU$131.77k	0.036% A$ 205.7k
Ingrid Player	Independent Non-Executive Director	less than a year	no data	0.015% A$ 84.7k
James Hall	Independent Non-Executive Director	less than a year	no data	0.065% A$ 367.2k

1.8yrs

Average Tenure

58yo

Average Age

Experienced Board: IDX's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Integral Diagnostics Management

Management criteria checks 2/4

Key information

Recent management updates

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Integral Diagnostics Limited Appoints Toby Hall as Director

Recent updates

First half dividend of AU$0.025 announced

First half 2024 earnings released: AU$0.29 loss per share (vs AU$0.069 profit in 1H 2023)

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Investor sentiment deteriorates as stock falls 27%

Integral Diagnostics Limited Appoints Toby Hall as Director

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023

Full year 2023 earnings released: EPS: AU$0.11 (vs AU$0.07 in FY 2022)

Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023

Integral Diagnostics Limited Announces Board Changes

Upcoming dividend of AU$0.025 per share at 2.0% yield

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023

Now 21% undervalued

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

Independent Non-Executive Director recently bought AU$114k worth of stock

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Year Ended June 30, 2022, Payable on October 5, 2022

Full year 2022 earnings released

Investor sentiment improved over the past week

Integral Diagnostics Limited Announces Appointment of Andrew Fay as an Independent Non-Executive Director

Now 21% undervalued after recent price drop

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Integral Diagnostics Limited (ASX:IDX) ) agreed to acquire Exact Radiology Pty Ltd for NZD 33.3 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Exact Radiology Pty Ltd for approximately AUD 39 million.

Executive Director recently bought AU$70k worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Integral Diagnostics Limited Announces the Distribution for the Six Months Ended December 31, 2021, Payable on April 4, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.12 in FY 2020)

Executive Director has left the company

First half 2021 earnings released: EPS AU$0.10 (vs AU$0.062 in 1H 2020)

Revenue beats expectations

Integral Diagnostics Limited Announces Retirement of Dr. Chien Ho as Executive Director, Effective on March 1, 2021

Integral Diagnostics Limited to Report First Half, 2021 Results on Feb 22, 2021

New 90-day high: AU$4.48

New 90-day high: AU$4.42

Executive Director recently sold AU$266k worth of stock

Executive Director recently sold AU$123k worth of stock

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Ascot Radiology Limited for NZD 54 million.

Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Ascot Radiology Limited.

New 90-day high - AU$4.30

Earnings released

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age